| Issue Date | Title | Author(s) |
| 1-Jun-2021 | Idiopathic pulmonary fibrosis: Disease mechanisms and drug development | Spagnolo, P; Kropski, JA; Jones, MG; Lee, JS; Rossi, G, et al |
| 27-Sep-2021 | Management of acute exacerbation of idiopathic pulmonary fibrosis in specialised and non-specialised ILD centres around the world | Polke, M; Kondoh, Y; Wijsenbeek, M; Cottin, V; Walsh, SLF, et al |
| 1-Jul-2024 | Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis | Kreuter, M; Lee, JS; Tzouvelekis, A; Oldham, JM; Molyneaux, PL, et al |
| 1-Jul-2021 | Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis | Kreuter, M; Lee, JS; Tzouvelekis, A; Oldham, JM; Molyneaux, PL, et al |
| 24-Jun-2020 | Shedding light on developmental drugs for idiopathic pulmonary fibrosis | Spagnolo, P; Bonella, F; Ryerson, CJ; Tzouvelekis, A; Maher, TM, et al |
| 1-Nov-2017 | Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study | Herazo-Maya, JD; Sun, J; Molyneaux, PL; Li, Q; Villalba, JA, et al |